Cyclosporine lymphocyte maximum level

Abstract

Objectives: To determine the relationship between clinical outcome, lymphocyte count (LC), and cyclosporine (CsA) lymphocyte maximum level (LTmL) in kidney transplant recipients.

Materials and Methods: CsA LTmL was determined in patients with biopsy-proven graft dysfunction and in patients with normal graft function. Clinical outcome was compared according to CsA LTmL, dosage, blood trough (C0) and maximum (Cmax) levels, hematocrit level, and LC.

Results: Rejecting patients had significantly lower LTmL than did those with normal graft function (27 ± 11 pg/Lc vs 71 ± 79 pg/Lc; P < 0.01) and similar LTmL to those with nephrotoxicity (27 ± 8 pg/Lc). Patients with normal graft function exhibited significantly lower LC (0.001292 ± 696 x 109/L) and serum creatinine levels (88.4 ± 35 µmol/L) when compared with rejecting patients (0.001717 ± 364 x 109/L, 132.6 ± 8.8 µmol/L) and those with nephrotoxicity (0.001884 ± 582 x 109/L, 123.7 ± 8.8 µmol/L) (P < 0.03, P < 0.001). No significant difference was observed among the 3 groups with regard to CsA dosage, C0, Cmax, mycophenolate mofetil (MMF) dosage, and mycophenolic acid (MPA) plasma levels. CsA LTmL closely correlated in an exponential (R2 = 0.98) and linear (R2 = 0.35) fashion with LC and hematocrit level, respectively. Conversely, CsA Cmax failed to correlate with C0 and these 2 latter parameters. Weak correlations were observed between CsA Cmax and its corresponding LTmL.

Conclusions: CsA LTmL appears to correlate better than CsA Cmax with rejection-free outcome and LC. An increase in hematocrit appears to have an adverse effect on CsA lymphocyte binding. CsA LTmL may offer a new alternative for CsA monitoring in kidney transplantation.